.jpg)
.png)
“Security is mostly a superstition. It does not exist in nature, nor do the children of men as whole experience it. Avoiding danger is no safer in the long run than outright exposure. Life is either a daring adventure or nothing.” – Helen Keller
Article By:
It was an honor and privilege for the Southeast Lipid Association (SELA) to host the National Lipid Association (NLA) Scientific Sessions in Orlando, Fla. this past May 2014. Excellent topics and presenters offered practical knowledge for integrating the latest clinical research guidelines into practice. I was pleased to chair the Abstracts Committee, and was impressed with all the submissions. Marisa Schoen, BA, was recognized with the First Place Young Investigator Award.
Article By:
Diplomate, Accreditation Council of Clinical Lipidology
Case:
Article By:
Winter Park, FL
Diplomate, American Board of Clinical Lipidology
Atherogenic lipoproteins play a critical role in the initiation and progression of vascular atherosclerosis, and decades of research have clearly demonstrated the benefits of lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) events. However, despite the publication of guidelines for management of dyslipidemia by numerous professional societies, there still are inadequate numbers of patients receiving evidence-based therapy.
Article By:
Co-director, Women’s Heart Care
Charleston, SC
Diplomate, American Board of Clinical Lipidology
Blood Lipid Response to Physical Activity and Exercise Training
Article By:
Durham, NC
Diplomate, Accreditation Council of Clinical Lipidology
The Heart Protection Study 2 — Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial was a randomized, double-blind, multicenter clinical trial.1 Enrolled subjects were between ages 50 and 80 and had a history of vascular disease. After a four-week run-in phase with simvastatin 40mg daily (ezetimibe was added if total cholesterol remained >135 mg/dL), subjects were randomized to extended-release niacin-laropiprant or matching placebo.
Article By:
Richmond, VA
Diplomate, Accreditation Council of Clinical Lipidology
Richmond, VA
I have in mind a prospective clinical trial in which I study a common children’s phenomenon, detailing the differences between genders, location, ethnicity, biometrics, dental data, monetary value, etc. It’s a common phenomenon that most parents have photos of and have experienced ourselves. I’m sure we could generate a lot of highly statistically significant data and make many useful insights.
Article By:
Johns Hopkins University School of Medicine
Director, Baltimore Lipid Center
Diplomate, American Board of Clinical Lipidology
This issue of LipidSpin is dedicated to “Evaluating Published Clinical Trials and Translating Them into Practice.” Clinical trials are the basis for advancing our knowledge of effective therapies in medicine. Well-conducted clinical trials, particularly those with results that can be replicated, traditionally have been used to develop practice guidelines.
Article By:
Assistant Professor, University of Central Florida College of Medicine
Cocoa Beach, FL
Diplomate, American Board of Clinical Cardiology
Over the course of my 36-year career, the practice of medicine has changed dramatically. When I was an intern at Georgetown University Hospital, we treated heart attacks with oxygen, morphine, and sometimes not much more than prayers. Barely anyone at that time could conceive of doing a cardiac catheterization on an acute myocardial infarction.
Article By:
Founder, MIMA Century Research
Associate Professor of Cardiovascular Medicine
University of Central Florida College of Medicine
Melbourne, FL
Diplomate, American Board of Clinical Lipidology
I write this with the holiday season having just passed us. As I sit back and reflect on the past year, it occurs to me that we have much to be thankful for! This past year we embraced the extensive statin safety report from the National Lipid Association. This was followed in September by the release of our Recommendations for the Patient-Centered Management of Dyslipidemia.
Article By:
Diplomate, American Board of Clinical Lipidology